Three months of romosozumab did not improve hip bone strength, but 12 months did, supporting completion of the full regimen in patients with osteoporosis.
News|Articles|March 11, 2024
Clinical Quiz: ACR Guideline for the Management of Gout
Author(s)Lana Pine
Test your knowledge of the ACR's guideline for the management of gout with this quiz!
Advertisement
In 2020, a team of clinicians at the American College of Rheumatology (ACR) published 42 recommendations for the treatment of gout, including the initiation of urate-lowering therapy, treat-to-target management strategies, and concomitant therapy.
Test your knowledge of gout treatment and management with this quiz:
What is the strongly recommended first-line agent for the treatment of gout, particularly for patients with moderate-to-severe chronic kidney disease (CKD) stage ≥3?
Reference
Gout Clinical Practice Guidelines. June 2020. Accessed March 11, 2024. https://rheumatology.org/gout-guideline#2020-gout-guideline.
Advertisement
Related to this article
The new 30-mg/5-mL formulation offers an alternative for adults who have difficulty swallowing capsules.
On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Advertisement
Advertisement